Dr. Botta on the Diagnosis and Treatment of ESCC
Gregory Botta, MD, PhD, discusses the diagnosis and treatment of patients with esophageal squamous cell carcinoma.
Dr. Botta on Unmet Needs in the Salvage Setting of GI Cancers
Gregory Botta, MD, PhD, discusses unmet needs in the salvage setting of gastrointestinal cancers.
Dr. Botta on the Rationale of Investigating CT041 in Gastric and Pancreatic Cancers
Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.
Dr. Botta on the Evaluation of CT041 in Gastric and Pancreatic Cancer
Gregory Botta, MD, PhD, discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.
Assessing the Full Potential of ctDNA in Colorectal Cancer
Gregory P. Botta, MD, PhD, highlights key trials of interest exploring ctDNA analyses to better inform treatment decisions for patients with rectal cancers.
CIRCULATE-Japan: Using ctDNA to Guide Adjuvant Therapy in Colorectal Cancer
What to know about the design and results of the CIRCULATE-Japan study in colorectal cancer, in terms of using ctDNA analyses to help inform treatment decisions in the postoperative setting.
Future Role of ctDNA in Pancreatic Cancer
Current trials investigating the potential of ctDNA analyses in pancreatic cancer.
Personalized/Tumor-Informed ctDNA and Patient Survival in Pancreatic Cancer
Dr Gregory P. Botta reacts to results of a study that recently explored the association of tumor-informed and personalized ctDNA with patient survival outcomes in pancreatic cancer, as presented at ASCO GI 2022.
ctDNA Testing in Pancreatic Cancer
The potential clinical applications of ctDNA analyses in pancreatic cancer.
MRD Testing in Solid Tumors
The present role of minimal residual disease in solid tumor cancers, and current evaluations further exploring its potential in pancreatic and colorectal cancer.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512